APOE and Alzheimer disease: Bioinformatic analysis showed that miR-650 may target the expression of three AD-related components: APOE, presenilin 1 (PSEN1), and cyclin-dependent kinase 5 (CDK5), with recent findings confirming that miR-650 may reduce in vitro the expression of APOE, PSEN1, and CDK5 [78].